Enzon reports PEG-Intron Phase III data

ENZN and partner Schering-Plough (SGP) said data from an international Phase III trial in 1,530 treatment-nave patients showed that 1.5 ug/kg weekly PEG-Intron (peginterferon alfa-2b) injection plus R...